Johnson & Johnson (JNJ) is facing the first lawsuits in Britain over allegations that its talc products cause cancer, reported Reuters. KP Law said it filed the case at the English High Court on Tuesday against J&J and Kenvue UK Limited, a subsidiary of Kenvue (KVUE), on behalf of more than 3,000 people, the report noted. J&J referred queries to Kenvue, which it said “retained the responsibility and any purported liability for talc-related litigation outside of the United States and Canada” and Kenvue said in a statement that J&J baby powder “did not contain asbestos, and does not cause cancer,” Reuters added.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on JNJ:
- Johnson & Johnson Stock (JNJ) Flattens as it Faces U.K. Talcum Powder Cancer Claims
- Johnson & Johnson’s Tecvayli regimen improves survival in multiple myeloma trial
- Why Dividend King Johnson & Johnson (JNJ) Excels in Volatile Markets
- 3 Best Dividend Aristocrat Stocks to Buy Now, 10/15/2025
- Johnson & Johnson price target raised to $210 from $185 at Argus